Idorsia Ltd (IDIA) - Total Liabilities

Latest as of March 2026: CHF1.66 Billion CHF ≈ $2.09 Billion USD

Based on the latest financial reports, Idorsia Ltd (IDIA) has total liabilities worth CHF1.66 Billion CHF (≈ $2.09 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Idorsia Ltd - Total Liabilities Trend (2016–2025)

This chart illustrates how Idorsia Ltd's total liabilities have evolved over time, based on quarterly financial data. See Idorsia Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Idorsia Ltd Competitors by Total Liabilities

The table below lists competitors of Idorsia Ltd ranked by their total liabilities.

Company Country Total Liabilities
LegalZoom.com Inc
NASDAQ:LZ
USA $344.95 Million
Sarawak Oil Palms Bhd
KLSE:5126
Malaysia RM1.42 Billion
Ningbo Donly Co Ltd
SHE:002164
China CN¥1.09 Billion
Varroc Engineering Limited
NSE:VARROC
India Rs30.34 Billion
Kunshan Top A Intelligent Equipment
SHE:300836
China CN¥788.71 Million
Accel Entertainment Inc
NYSE:ACEL
USA $794.90 Million
Lecron Energy Saving Materials
SHE:300343
China CN¥572.19 Million
Sam Hwa Capaci
KO:001820
Korea ₩58.96 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Idorsia Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Idorsia Ltd worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.60 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.41 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 3.45 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Idorsia Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Idorsia Ltd (2016–2025)

The table below shows the annual total liabilities of Idorsia Ltd from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 CHF1.60 Billion
≈ $2.03 Billion
-6.69%
2024-12-31 CHF1.72 Billion
≈ $2.17 Billion
+16.98%
2023-12-31 CHF1.47 Billion
≈ $1.86 Billion
-6.16%
2022-12-31 CHF1.57 Billion
≈ $1.98 Billion
+13.52%
2021-12-31 CHF1.38 Billion
≈ $1.74 Billion
+62.23%
2020-12-31 CHF849.88 Million
≈ $1.07 Billion
+1.19%
2019-12-31 CHF839.85 Million
≈ $1.06 Billion
+12.11%
2018-12-31 CHF749.14 Million
≈ $947.12 Million
+35.62%
2017-12-31 CHF552.37 Million
≈ $698.34 Million
+35.67%
2016-12-31 CHF407.15 Million
≈ $514.75 Million
--

About Idorsia Ltd

SW:IDIA Switzerland Biotechnology
Market Cap
$1.45 Billion
CHF1.14 Billion CHF
Market Cap Rank
#8973 Global
#119 in Switzerland
Share Price
CHF4.51
Change (1 day)
-3.10%
52-Week Range
CHF1.87 - CHF4.79
All Time High
CHF33.62
About

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more